Published in Paediatr Drugs on August 01, 2016
Model-based Versus Traditional Warfarin Dosing in Children (WATCH) | NCT02475863
The role of heterogeneity in asthma: a structure-to-function perspective. Clin Transl Med (2017) 0.75
Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med (2003) 7.51
A randomized trial of genotype-guided dosing of warfarin. N Engl J Med (2013) 7.18
Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.88
A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med (2013) 4.27
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet (2009) 3.83
Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med (2011) 3.80
Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet (2006) 3.72
Heterogeneity of therapeutic responses in asthma. Br Med Bull (2000) 2.86
Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther (2013) 2.70
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40
Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics (2009) 2.35
Tailored second-line therapy in asthmatic children with the Arg(16) genotype. Clin Sci (Lond) (2013) 2.25
In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood (2010) 1.93
Maturation of the hemostatic system during childhood. Blood (1992) 1.89
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax (2006) 1.86
A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet (2009) 1.78
Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J Allergy Clin Immunol (2009) 1.61
Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol (2001) 1.56
Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients. Lung Cancer (2012) 1.52
Different inflammatory phenotypes in adults and children with acute asthma. Eur Respir J (2011) 1.50
Challenges in interpreting the evidence for genetic predictors of ototoxicity. Clin Pharmacol Ther (2013) 1.46
Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood (1999) 1.41
Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol (2007) 1.38
Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J (2009) 1.28
Gene Expression by Mouse Inner Ear Hair Cells during Development. J Neurosci (2015) 1.28
VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood (2011) 1.22
Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs (2000) 1.15
Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J (2007) 1.13
Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity. Clin Pharmacol Ther (2014) 1.13
Genetics of cisplatin ototoxicity: confirming the unexplained? Clin Pharmacol Ther (2013) 1.11
Predictors of symptoms are different from predictors of severe exacerbations from asthma in children. Chest (2011) 1.10
Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood (2011) 1.05
Genetic and clinical determinants influencing warfarin dosing in children with heart disease. Pediatr Cardiol (2012) 0.97
Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. Br J Clin Pharmacol (2014) 0.97
Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients. Drug Metab Pharmacokinet (2011) 0.92
Warfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithms. Eur J Clin Pharmacol (2013) 0.91
Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients. Drug Metab Pharmacokinet (2012) 0.88
Genetics-based pediatric warfarin dosage regimen derived using pharmacometric bridging. J Pediatr Pharmacol Ther (2013) 0.87
Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting β2-agonists: results of the PACMAN cohort. Pharmacogenomics (2013) 0.84
VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatr Blood Cancer (2014) 0.84
Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet (2015) 0.83
Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity. Clin Pharmacol Ther (2013) 0.81
Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics. Clin Pharmacokinet (2016) 0.81
Progress towards the integration of pharmacogenomics in practice. Hum Genet (2014) 0.81
Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics (2015) 0.80
Childhood asthma exacerbations and the Arg16 β2-receptor polymorphism: A meta-analysis stratified by treatment. J Allergy Clin Immunol (2016) 0.80
The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population. Br J Haematol (2014) 0.80
A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children. BMC Med Inform Decis Mak (2015) 0.80
Genetic variation in Otos is associated with cisplatin-induced ototoxicity. Pharmacogenomics (2014) 0.79
Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms. J Pediatr Hematol Oncol (2013) 0.79
Influence of β(2)-adrenergic receptor polymorphisms on asthma exacerbation in children with severe asthma regularly receiving salmeterol. Ann Allergy Asthma Immunol (2013) 0.79
GLCCI1 rs37973 does not influence treatment response to inhaled corticosteroids in white subjects with asthma. J Allergy Clin Immunol (2013) 0.79
Pharmacogenetics-based warfarin dosing in children. Pharmacogenomics (2014) 0.79
ADRB2 Arg16 and the need for collaboration in childhood asthma pharmacogenomics. Pharmacogenomics (2013) 0.78
Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis. Thromb Haemost (2015) 0.77
Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. Ther Drug Monit (2015) 0.77
Evaluation and Management of Hearing Loss in Survivors of Childhood and Adolescent Cancers: A Report From the Children's Oncology Group. Pediatr Blood Cancer (2016) 0.76
SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma. Cancer Med (2015) 0.76
Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity". Clin Pharmacol Ther (2014) 0.76
Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids. Pharmacogenomics (2014) 0.76